Finance
S&P 500 7,694.05 +27.45 +0.36% Dow 53,306.07 +244.12 +0.46% Nasdaq 26,389.30 +171.47 +0.65% NYSE Composite 24,618.46 +122.91 +0.50% Russell 2000 2,963.86 +10.69 +0.36% VIX 15.10 -0.10 -0.66%

PMCB · PharmaCyte Biotech, Inc.

NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD

PharmaCyte Biotech Inc (PMCB)

NASDAQ NMS - GLOBAL MARKET Biotechnology
Options chain →
$0.49 -0.01 (-2.10%)
● Market open
DAY'S RANGE $0.49
$0.49 $0.49
52-WEEK RANGE $0.49
$0.48 $1.51

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$5.2M
P/E (TTM1)—
EPS2 (TTM)$-2.65
Div Yield—
Beta30.73
Volume100
Open0.49
Prev Close0.50
Bid / Ask0.48 / 0.56
Next Earnings 2026-09-14

Analyst Recommendations

Strong buy 0 Buy 0 Hold 3 Sell 1 Strong sell 2

Aggregate ratings for 2023-02-01 (6 analysts polled by Finnhub) — consensus count.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
PMCB -32.58%
vs S&P 500 -44.29%
1-YEAR RETURN
PMCB -47.60%
vs S&P 500 -66.58%
6-MONTH RETURN
PMCB -30.67%
3-MONTH RETURN
PMCB -39.00%

Valuation Measures & Ratios

Enterprise Value4-$12.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)147.99
Price / Book70.22
EV4 / Revenue-318.28
EV4 / EBITDA—
Profit Margin-4184.21%
Operating Margin-3469.42%
Return on Equity (ROE8)-50.28%
Return on Assets (ROA9)-38.14%
Avg Volume (3M)155,590
Quarterly history (5 periods)
Measure Jan '26Oct '25Jul '25Jan '25Oct '24
Market cap — $5.6M $7.0M $11.1M $6.9M
P/E — -0.27 0.67 0.61 0.28
Price/Book — 0.16 0.16 0.28 0.16
ROE — -57.59% 24.19% 45.43% 55.52%
ROA — -36.25% 23.38% 41.72% 43.78%

Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.

Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short208,161
Change from Prior Settlement-28.70%
% of Float—
Days to Cover (Short Ratio)2.08

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

  • Latest SEC filing is Form 10-K, filed 2026-07-29; review it for current changes and risks. SEC EDGAR ↗

Potential concerns

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

No accessible free API for these — links go to the source directly.

Morningstar Motley Fool MarketBeat

Financials

Income statement

Line item Jan '26Oct '25Jul '25Jan '25Oct '24Jul '24Jan '24Oct '23
Revenue $0 $0 $0 $0 $0 $0 $0 $0
Gross profit — — — — — — — —
Operating income -$2.1M -$1.4M -$848.3K -$960.3K -$1.1M -$1.3M -$1.9M -$1.4M
Net income $746.9K -$7.4M -$8.4M -$3.0M -$1.5M $23.4M -$619.5K $2.8M
EPS (diluted) $-0.17 $-1.24 $-1.23 $-0.44 $-0.39 $1.90 $-0.65 $-0.26
EPS (basic) $-0.17 $-1.24 $-1.23 $-0.44 $-0.39 $1.90 $-0.65 $-0.26

Balance sheet

Line item Apr '26Jan '26Oct '25Jul '25Apr '25Jan '25Oct '24Jul '24
Total assets $46.8M $55.9M $56.0M $45.1M $55.2M $43.8M $55.1M $70.2M
Total liabilities $11.8M $16.5M $19.4M $1.5M $3.3M $3.6M $11.6M $17.2M
Stockholders' equity $33.3M $38.1M $35.2M $43.6M $51.9M $40.3M $43.5M $47.7M
Total current assets $37.4M $20.7M $23.0M $19.1M $22.4M $17.0M $21.3M $32.9M
Total current liabilities $826.4K $1.7M $1.6M $1.1M $2.9M $1.2M $4.8M $7.5M
Cash & equivalents $18.6M $20.2M $15.4M $13.2M $15.2M $16.4M $20.8M $32.6M

Cash flow

Line item Apr '26Jan '26Oct '25Jul '25Apr '25Jan '25Oct '24Jul '24
Operating cash flow -$1.4M -$786.8K -$979.5K -$2.0M -$1.0M -$509.9K -$1.1M -$373.3K
Investing cash flow $0 $5.0M -$3.0M $0 $0 $0 $0 -$7.0M
Financing cash flow -$169.8K $543.8K $6.2M $0 -$171.5K -$3.9M -$10.7M -$10.2M
Share-based compensation $0 $771.5K $60.5K $60.5K $0 -$341.8K $119.2K $222.7K
Change in accounts receivable — — — — — — — —
Change in inventory — — — — — — — —

Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.

Institutional holders

SEC Form 13F filers holding PMCB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

Institutional ownership is not available for this symbol right now.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-12 to 2026-01-07

Recent transactions

  • Most recent: Silverman Joshua (CEO and President) — Open market purchase of 40,000 shares on 2026-01-07.

Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.

Insider purchases & sales, last 6 months

Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0

Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.

Insider roster

NameTitleMost Recent TransactionDateShares
Silverman JoshuaCEO and PresidentOpen market purchase2026-01-0740,000
SCHECHTER JONATHANDirectorOpen market purchase2026-01-0720,000
WEINSTEIN ROBERTDirectorGrant / award2025-12-1275,000
WALKER WAYNE REMELLDirectorGrant / award2025-12-1237,500
Abecassis Michael MDirectorGrant / award2025-12-1237,500

Recent transactions

DateInsiderTitleTransactionSharesPrice
2026-01-07Silverman JoshuaCEO and PresidentOpen market purchase 40,000$0.83
2026-01-07SCHECHTER JONATHANDirectorOpen market purchase 20,000$0.84
2026-01-06Silverman JoshuaCEO and PresidentOpen market purchase 30,000$0.79
2026-01-06SCHECHTER JONATHANDirectorOpen market purchase 20,000$0.79
2026-01-05Silverman JoshuaCEO and PresidentOpen market purchase 30,000$0.78
2026-01-05SCHECHTER JONATHANDirectorOpen market purchase 20,000$0.78
2025-12-12WEINSTEIN ROBERTDirectorGrant / award 75,000$0.00
2025-12-12WEINSTEIN ROBERTDirectorTax withholding 33,750$1.02
2025-12-12WALKER WAYNE REMELLDirectorGrant / award 37,500$0.00
2025-12-12WALKER WAYNE REMELLDirectorTax withholding 16,875$1.02
2025-12-12Silverman JoshuaCEO and PresidentGrant / award 575,000$0.00
2025-12-12Silverman JoshuaCEO and PresidentTax withholding 258,750$1.02
2025-12-12SCHECHTER JONATHANDirectorGrant / award 150,000$0.00
2025-12-12SCHECHTER JONATHANDirectorTax withholding 67,500$1.02
2025-12-12Abecassis Michael MDirectorGrant / award 37,500$0.00
2025-12-12Abecassis Michael MDirectorTax withholding 16,875$1.02

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR submissions · updated 2026-09-03 11:59 UTC

FiledFormReport periodOfficial filing
2026-07-2910-K2026-04-30 View on SEC.gov →
2026-04-0242026-03-31 View on SEC.gov →
2026-04-0242026-03-31 View on SEC.gov →
2026-04-0242026-03-31 View on SEC.gov →
2026-04-0242026-03-31 View on SEC.gov →
2026-04-028-K2026-03-30 View on SEC.gov →
2026-03-1842026-03-17 View on SEC.gov →
2026-03-1710-Q2026-01-31 View on SEC.gov →
2026-01-0742026-01-05 View on SEC.gov →
2026-01-0742026-01-05 View on SEC.gov →
2025-12-1810-Q2025-10-31 View on SEC.gov →
2025-12-1242025-04-25 View on SEC.gov →

Headlines about PMCB (PharmaCyte Biotech, Inc.). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist